<DOC>
	<DOCNO>NCT00819195</DOCNO>
	<brief_summary>The purpose study determine whether glatiramer acetate ( Copaxone ) induce anti-inflammatory type II monocyte development treatment MS , antigen present cell ( APC ) promote Th2 Treg differentiation naïve T cell .</brief_summary>
	<brief_title>Anti-Inflammatory Type II Monocyte Induction Glatiramer Acetate ( Copaxone ) Treatment Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Relapsingremitting ( RR ) MS patient ( McDonald criterion ) Ages 1855 Males female EDSS score ≤5 No prior treatment Copaxone Prior treatment corticosteroid interferonbeta ( 1a 1b ) acceptable , provide washout period least one month Treatment Tysabri , Novantrone cyclophosphamide Treatment immunomodulatory therapy ( e.g . imuran , mycophenolate methotrexate ) Primaryprogressive ( PP ) secondaryprogressive ( SP ) multiple sclerosis Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>relapsing-remitting</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>Copaxone</keyword>
	<keyword>glatiramer acetate</keyword>
	<keyword>MS</keyword>
</DOC>